You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFlumethasone
Accession NumberDB00663  (APRD00975)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionFlumethasone is a moderately potent difluorinated corticosteroid ester with anti-inflammatory, antipruritic and vasoconstrictive properties. As it is a privalate salt, its anti-inflammatory action is concentrated at the site of application. This local effect on diseased areas results in a prompt decrease in inflammation, exudation and itching.
Structure
Thumb
Synonyms
Flumetason
Flumetasona
Flumétasone
Flumetasone
Flumetasonum
External Identifiers
  • RS 2177
  • U 10974
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Locacorten .03%cream.03 %topicalNovartis Pharmaceuticals Canada Inc1966-12-311999-05-19Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CersonRiemser
LocacortenNovartis
LocortenNovartis
TestohgenMaeda Yakuhin
Brand mixtures
NameLabellerIngredients
Locacorten VioformPaladin Labs Inc
Locacorten Vioform EardropsPaladin Labs Inc
LocasalenNovartis Pharmaceuticals Canada Inc
PMS-flumethasone-clioquinolPharmascience Inc
Salts
Name/CASStructureProperties
Flumethasone acetate
ThumbNot applicableDBSALT001651
Flumethasone pivalate
2002-29-1
Thumb
  • InChI Key: JWRMHDSINXPDHB-OJAGFMMFSA-N
  • Monoisotopic Mass: 494.247995294
  • Average Mass: 494.5679
DBSALT001004
Categories
UNIILR3CD8SX89
CAS number2135-17-3
WeightAverage: 410.458
Monoisotopic: 410.190480328
Chemical FormulaC22H28F2O5
InChI KeyWXURHACBFYSXBI-GQKYHHCASA-N
InChI
InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1
IUPAC Name
(1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-difluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1(F)[C@@]2([H])C[[email protected]](F)C2=CC(=O)C=C[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • Progestogin-skeleton
  • 21-hydroxysteroid
  • Pregnane-skeleton
  • 20-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • 3-oxosteroid
  • 17-hydroxysteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • 9-halo-steroid
  • 6-halo-steroid
  • Halo-steroid
  • Oxosteroid
  • Delta-1,4-steroid
  • Alpha-hydroxy ketone
  • Cyclic alcohol
  • Tertiary alcohol
  • Ketone
  • Halohydrin
  • Fluorohydrin
  • Secondary alcohol
  • Cyclic ketone
  • Organofluoride
  • Alcohol
  • Primary alcohol
  • Hydrocarbon derivative
  • Organic oxide
  • Carbonyl group
  • Organic oxygen compound
  • Alkyl halide
  • Alkyl fluoride
  • Organooxygen compound
  • Organohalogen compound
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of contact dermatitis, atopic dermatitis, exczema, psoriasis, diaper rash and other skin conditions
PharmacodynamicsFlumethasone pivalate is a moderately potent difluorinated corticosteroid ester with anti-inflammatory, antipruritic and vasoconstrictive properties. As it is a privalate salt, its anti-inflammatory action is concentrated at the site of application. This local effect on diseased areas results in a prompt decrease in inflammation, exudation and itching.
Mechanism of actionFlumethasone is a glucocorticoid receptor agonist. This complex binds to the nucleus causing a variety of genetic activation and repressions. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Flumethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin.
Related Articles
AbsorptionMinimal if applied topically
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Primarily hepatic

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityCan lead to signs of irritation such as burning sensation, itching or skin rash at the site of application; hypersensitivity reactions.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9877
Blood Brain Barrier+0.9664
Caco-2 permeable+0.5146
P-glycoprotein substrateSubstrate0.8083
P-glycoprotein inhibitor IInhibitor0.5199
P-glycoprotein inhibitor IINon-inhibitor0.7781
Renal organic cation transporterNon-inhibitor0.8453
CYP450 2C9 substrateNon-substrate0.9008
CYP450 2D6 substrateNon-substrate0.908
CYP450 3A4 substrateSubstrate0.7477
CYP450 1A2 substrateNon-inhibitor0.9087
CYP450 2C9 inhibitorNon-inhibitor0.9052
CYP450 2D6 inhibitorNon-inhibitor0.9591
CYP450 2C19 inhibitorNon-inhibitor0.9337
CYP450 3A4 inhibitorNon-inhibitor0.7935
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9005
Ames testNon AMES toxic0.8008
CarcinogenicityNon-carcinogens0.9259
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4249 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9912
hERG inhibition (predictor II)Non-inhibitor0.6792
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
PackagersNot Available
Dosage forms
FormRouteStrength
Creamtopical.03 %
Creamtopical
Dropsotic
Ointmenttopical
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point219 °C (base only)Not Available
water solubility0.392 mg/LNot Available
logP3.86HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0853 mg/mLALOGPS
logP1.91ALOGPS
logP1.34ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)12.42ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity102.32 m3·mol-1ChemAxon
Polarizability41.25 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Lincoln, F.H., Schneider, W.P. and Spero, G.B.; U.S. Patent 3,557,158; January 19, 1971;
assigned to The Upjohn Co.

General ReferencesNot Available
External Links
ATC CodesD07AB03D07XB01S02CA02D07BB01D07CB05
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Flumethasone is combined with 1,10-Phenanthroline.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Flumethasone.
AldesleukinFlumethasone may decrease the antineoplastic activities of Aldesleukin.
Aluminum hydroxideThe bioavailability of Flumethasone can be decreased when combined with Aluminum hydroxide.
Aluminum phosphateThe bioavailability of Flumethasone can be decreased when combined with Aluminum phosphate.
AmbenoniumThe risk or severity of adverse effects can be increased when Flumethasone is combined with Ambenonium.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Flumethasone.
AmiodaroneThe serum concentration of Flumethasone can be increased when it is combined with Amiodarone.
Amphotericin BFlumethasone may increase the hypokalemic activities of Amphotericin B.
AprepitantThe serum concentration of Flumethasone can be increased when it is combined with Aprepitant.
AtazanavirThe serum concentration of Flumethasone can be increased when it is combined with Atazanavir.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Flumethasone.
BazedoxifeneThe serum concentration of Flumethasone can be increased when it is combined with Bazedoxifene.
BendroflumethiazideFlumethasone may increase the hypokalemic activities of Bendroflumethiazide.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Flumethasone.
Bismuth SubcitrateThe bioavailability of Flumethasone can be decreased when combined with Bismuth Subcitrate.
BoceprevirThe serum concentration of Flumethasone can be increased when it is combined with Boceprevir.
BumetanideFlumethasone may increase the hypokalemic activities of Bumetanide.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Flumethasone.
Calcium carbonateThe bioavailability of Flumethasone can be decreased when combined with Calcium carbonate.
CarbamazepineThe serum concentration of Flumethasone can be decreased when it is combined with Carbamazepine.
CeritinibFlumethasone may increase the hyperglycemic activities of Ceritinib.
CeritinibThe serum concentration of Flumethasone can be increased when it is combined with Ceritinib.
ChlorothiazideFlumethasone may increase the hypokalemic activities of Chlorothiazide.
ChlorotrianiseneThe serum concentration of Flumethasone can be increased when it is combined with Chlorotrianisene.
ChlorthalidoneFlumethasone may increase the hypokalemic activities of Chlorthalidone.
CholestyramineCholestyramine can cause a decrease in the absorption of Flumethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ClarithromycinThe serum concentration of Flumethasone can be increased when it is combined with Clarithromycin.
CobicistatThe serum concentration of Flumethasone can be increased when it is combined with Cobicistat.
ColesevelamColesevelam can cause a decrease in the absorption of Flumethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Flumethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Conjugated Equine EstrogensThe serum concentration of Flumethasone can be increased when it is combined with Conjugated Equine Estrogens.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Flumethasone.
CoumaphosThe risk or severity of adverse effects can be increased when Flumethasone is combined with Coumaphos.
DarunavirThe serum concentration of Flumethasone can be increased when it is combined with Darunavir.
DecamethoniumThe risk or severity of adverse effects can be increased when Flumethasone is combined with Decamethonium.
DeferasiroxThe risk or severity of adverse effects can be increased when Flumethasone is combined with Deferasirox.
DemecariumThe risk or severity of adverse effects can be increased when Flumethasone is combined with Demecarium.
DichlorvosThe risk or severity of adverse effects can be increased when Flumethasone is combined with Dichlorvos.
DienestrolThe serum concentration of Flumethasone can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of Flumethasone can be increased when it is combined with Diethylstilbestrol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Flumethasone.
DihydrotestosteroneFlumethasone may increase the fluid retaining activities of Dihydrotestosterone.
DonepezilThe risk or severity of adverse effects can be increased when Flumethasone is combined with Donepezil.
EchothiophateThe risk or severity of adverse effects can be increased when Flumethasone is combined with Echothiophate.
EdrophoniumThe risk or severity of adverse effects can be increased when Flumethasone is combined with Edrophonium.
EnzalutamideThe serum concentration of Flumethasone can be decreased when it is combined with Enzalutamide.
EstradiolThe serum concentration of Flumethasone can be increased when it is combined with Estradiol.
EstriolThe serum concentration of Flumethasone can be increased when it is combined with Estriol.
EstroneThe serum concentration of Flumethasone can be increased when it is combined with Estrone.
Etacrynic acidFlumethasone may increase the hypokalemic activities of Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Flumethasone can be increased when it is combined with Ethinyl Estradiol.
FenthionThe risk or severity of adverse effects can be increased when Flumethasone is combined with Fenthion.
FluoxymesteroneFlumethasone may increase the fluid retaining activities of Fluoxymesterone.
FosaprepitantThe serum concentration of Flumethasone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Flumethasone can be decreased when it is combined with Fosphenytoin.
FurosemideFlumethasone may increase the hypokalemic activities of Furosemide.
GalantamineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Flumethasone is combined with Gallamine Triethiodide.
GenisteinThe serum concentration of Flumethasone can be increased when it is combined with Genistein.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Flumethasone is combined with Ginkgo biloba.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Flumethasone.
HexestrolThe serum concentration of Flumethasone can be increased when it is combined with Hexestrol.
Huperzine AThe risk or severity of adverse effects can be increased when Flumethasone is combined with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Flumethasone.
HydrochlorothiazideFlumethasone may increase the hypokalemic activities of Hydrochlorothiazide.
HydroflumethiazideFlumethasone may increase the hypokalemic activities of Hydroflumethiazide.
IdelalisibThe serum concentration of Flumethasone can be increased when it is combined with Idelalisib.
IndacaterolIndacaterol may increase the hypokalemic activities of Flumethasone.
IndapamideFlumethasone may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of Flumethasone can be increased when it is combined with Indinavir.
IsoflurophateThe risk or severity of adverse effects can be increased when Flumethasone is combined with Isoflurophate.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Flumethasone.
ItraconazoleThe serum concentration of Flumethasone can be increased when it is combined with Itraconazole.
KetoconazoleThe serum concentration of Flumethasone can be increased when it is combined with Ketoconazole.
LopinavirThe serum concentration of Flumethasone can be increased when it is combined with Lopinavir.
MagaldrateThe bioavailability of Flumethasone can be decreased when combined with Magaldrate.
Magnesium carbonateThe bioavailability of Flumethasone can be decreased when combined with Magnesium carbonate.
Magnesium hydroxideThe bioavailability of Flumethasone can be decreased when combined with Magnesium hydroxide.
Magnesium oxideThe bioavailability of Flumethasone can be decreased when combined with Magnesium oxide.
Magnesium TrisilicateThe bioavailability of Flumethasone can be decreased when combined with Magnesium Trisilicate.
MalathionThe risk or severity of adverse effects can be increased when Flumethasone is combined with Malathion.
MefloquineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Mefloquine.
MemantineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Memantine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Flumethasone.
MestranolThe serum concentration of Flumethasone can be increased when it is combined with Mestranol.
MethyclothiazideFlumethasone may increase the hypokalemic activities of Methyclothiazide.
MethyltestosteroneFlumethasone may increase the fluid retaining activities of Methyltestosterone.
MetolazoneFlumethasone may increase the hypokalemic activities of Metolazone.
MifepristoneThe therapeutic efficacy of Flumethasone can be decreased when used in combination with Mifepristone.
MinaprineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Minaprine.
MitotaneThe serum concentration of Flumethasone can be decreased when it is combined with Mitotane.
MivacuriumMivacurium may increase the adverse neuromuscular activities of Flumethasone.
NefazodoneThe serum concentration of Flumethasone can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Flumethasone can be increased when it is combined with Nelfinavir.
NeostigmineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Neostigmine.
NevirapineThe serum concentration of Flumethasone can be decreased when it is combined with Nevirapine.
NicorandilThe risk or severity of adverse effects can be increased when Flumethasone is combined with Nicorandil.
OxandroloneFlumethasone may increase the fluid retaining activities of Oxandrolone.
OxymetholoneFlumethasone may increase the fluid retaining activities of Oxymetholone.
PentobarbitalThe serum concentration of Flumethasone can be decreased when it is combined with Pentobarbital.
PhenobarbitalThe serum concentration of Flumethasone can be decreased when it is combined with Phenobarbital.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Flumethasone.
PhenytoinThe serum concentration of Flumethasone can be decreased when it is combined with Phenytoin.
PhysostigmineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Physostigmine.
PiretanideFlumethasone may increase the hypokalemic activities of Piretanide.
Polyestradiol phosphateThe serum concentration of Flumethasone can be increased when it is combined with Polyestradiol phosphate.
PolythiazideFlumethasone may increase the hypokalemic activities of Polythiazide.
PosaconazoleThe serum concentration of Flumethasone can be increased when it is combined with Posaconazole.
PrimidoneThe serum concentration of Flumethasone can be decreased when it is combined with Primidone.
PyridostigmineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Pyridostigmine.
QuinestrolThe serum concentration of Flumethasone can be increased when it is combined with Quinestrol.
QuinethazoneFlumethasone may increase the hypokalemic activities of Quinethazone.
Rabies vaccineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Rabies vaccine.
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Flumethasone.
RifabutinThe serum concentration of Flumethasone can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Flumethasone can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Flumethasone can be decreased when it is combined with Rifapentine.
RitonavirThe serum concentration of Flumethasone can be increased when it is combined with Ritonavir.
RivastigmineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Rivastigmine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Flumethasone.
SaquinavirThe serum concentration of Flumethasone can be increased when it is combined with Saquinavir.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Flumethasone.
StanozololFlumethasone may increase the fluid retaining activities of Stanozolol.
Synthetic Conjugated Estrogens, AThe serum concentration of Flumethasone can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, BThe serum concentration of Flumethasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.
TacrineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Tacrine.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Flumethasone.
TelaprevirThe serum concentration of Flumethasone can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Flumethasone can be increased when it is combined with Telithromycin.
TestosteroneFlumethasone may increase the fluid retaining activities of Testosterone.
TiboloneThe serum concentration of Flumethasone can be increased when it is combined with Tibolone.
TorasemideFlumethasone may increase the hypokalemic activities of Torasemide.
TrichlorfonThe risk or severity of adverse effects can be increased when Flumethasone is combined with Trichlorfon.
TrichlormethiazideFlumethasone may increase the hypokalemic activities of Trichlormethiazide.
TubocurarineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Tubocurarine.
VoriconazoleThe serum concentration of Flumethasone can be increased when it is combined with Voriconazole.
WarfarinFlumethasone may increase the anticoagulant activities of Warfarin.
ZeranolThe serum concentration of Flumethasone can be increased when it is combined with Zeranol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Maier C, Runzler D, Schindelar J, Grabner G, Waldhausl W, Kohler G, Luger A: G-protein-coupled glucocorticoid receptors on the pituitary cell membrane. J Cell Sci. 2005 Aug 1;118(Pt 15):3353-61. [PubMed:16079279 ]
  4. Labeur M, Holsboer F: Molecular mechanisms of glucocorticoid receptor signaling. Medicina (B Aires). 2010;70(5):457-62. [PubMed:20920967 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Steroid binding
Specific Function:
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name:
SERPINA6
Uniprot ID:
P08185
Molecular Weight:
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23